SEC Form 4 · accession 0001562180-17-002007
Syndax Pharmaceuticals Inc · SNDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Keith Katkin
Director
Period of report
May 17, 2017
Accepted (ET)
May 19, 2017 · 11:26 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001395937
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $13.58 | May 17, 2017 | A | 10,000 | A | May 17, 2018 | May 17, 2027 | Common Stock | 10,000 | 10,000 | D |